

RECEIVED

APR 20 2000

TECH CENTER 1600/2900 Sheet 1 of 3

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DKT. NO. BAYER 11 C1	SERIAL NO. 09/458,014
	APPLICANT Jacques DUMAS, et al.	
	FILING DATE December 10, 1999	GROUP 1614


U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
<i>R</i>	AA 3,823,161	07/09/74	Lesser			
<i>R</i>	AB 5,130,331	07/14/92	Pascual			
<i>R</i>	AC 4,740,520	04/26/88	Hallenbach et al.			
<i>R</i>	AD 4,808,588	02/28/89	King			
<i>R</i>	AE 3,828,001	08/06/74	Broad et al.			
<i>R</i>	AF 3,424,760	01/28/69	Helsley et al.			
<i>R</i>	AG 3,424,761	01/28/69	Helsley et al.			
<i>R</i>	AH 3,424,762	01/28/69	Helsley et al.			
<i>R</i>	AI 4,071,524	01/31/78	Banitt			
<i>R</i>	AJ 4,111,683	09/05/78	Singer			
<i>R</i>	AK 4,437,878	03/20/88	Acker et al.			
<i>R</i>	AL 4,643,849	02/17/87	Hirai et al.			
<i>R</i>	AM 5,773,459	06/30/98	Tang et al.			
<i>R</i>	AN 5,508,288	04/16/96	Forbes et al.			
<i>R</i>	AO 4,062,861	12/13/77	Yukinaga et al.			
<i>R</i>	AP 4,111,680	09/05/78	Yukinaga et al.			
<i>R</i>	AQ 4,116,671	09/26/78	Yukinaga et al.			
<i>R</i>	AR 4,212,981	07/15/80	Yukinaga et al.			
<i>R</i>	AS 5,162,360	11/10/92	Creswell et al.			
<i>R</i>	AT 5,059,614	10/22/91	Lepage et al.			
<i>R</i>	AU 4,514,571	04/30/85	Nakai et al.			
<i>R</i>	AV 3,754,887	08/28/73	Brantley			
<i>R</i>	AW 3,743,498	07/03/73	Brantley			
<i>R</i>	AX 3,547,940	12/15/70	Brantley			
<i>R</i>	AY 3,646,059	02/29/72	Brantley			
<i>R</i>	AZ 5,319,099	06/07/94	Kamata et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
<i>R</i>	BA EP 335156	03/11/89	European				X
<i>R</i>	BB EP 459887	05/28/91	European				X
<i>R</i>	BC EP 371876	11/28/89	European				X
<i>R</i>	BD 93/24458	12/9/93	WO			X	
<i>R</i>	BE 2,146,707	10/12/95	Canada			X	

J. C. Jones 3/4/02




09/458,014

<i>R</i>	BF	96/40673	12/19/96	WO		X	
<i>R</i>	BG	94/14801	07/07/94	WO		X	
<i>R</i>	BH	94/25012	11/10/94	WO		X	
<i>R</i>	BI	1,590,870	06/10/81	England		X	
<i>R</i>	BJ	93/18028	09/16/93	WO		X	
<i>R</i>	BK	94/18170	08/18/94	WO		X	
<i>R</i>	BL	DE 3305866 A1	02/19/83	Germany			X
<i>R</i>	BM	95/02591	01/26/95	WO		X	
<i>R</i>	BN	95/13067	05/18/95	WO		X	
<i>R</i>	BO	95/07922	03/23/95	WO		X	
<i>R</i>	BP	95/31451	11/23/95	WO		X	
<i>R</i>	BQ	A1 96/40675	12/19/96	WO		X	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	BR	Dumas, J., "CAS Substructure," May 6, 1997, pages 1-29.
	BS	Scott, Bill, "Substructure (Patent Families)," August 11, 1997, pages 1-19.
	BT	Scott, Bill, "Substructure #1," November 25, 1997, pages 1-19.
	BU	Scott, Bill, "Substructure #2," November 25, 1997, pages 1-3.
	BV	Scott, Bill, "Selected compounds," November 25, 1997, pages 1-32.
<i>R</i>	BW	"Beilstein number" Collection, 28 pages. <i>NO DATE</i>
<i>R</i>	BX	"Beilstein Collection," 4 pages. <i>NO DATE</i>
<i>R</i>	BY	Scott, Bill, "Markush Patent Search," December 2, 1997, pages 1-28.
<i>R</i>	BZ	Scott, Bill, "Substructure Search," December 2, 1997, pages 1-51.
<i>R</i>	CA	Substructure Search, pages 1-30.
	CB	Derwent World Patents Index Search, pages 20-26.
	CC	Abstract of EP 116,932
	CD	Abstract of EP 676,395
	CE	Abstract of EP 202,538
	CF	Abstract of EP 16,371
<i>R</i>	CG	Avruch et al., "Raf meets Ras: completing the framework of a signal transduction pathway", TIBS 19; July 1994; pp. 279-2823.
<i>R</i>	CH	White, A. D., et al., "Heterocyclic Ureas: Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase as Hypocholesterolemic Agents," June 6, 1996, pages 4382-95.
<i>R</i>	CI	Audia, James E., et al., "Potent, Selective Tetrahydro- β -carboline Antagonists of the Serotonin 2B (5HT _{2B}) Contractile Receptor in the Rat Stomach Fundus," January 22, 1996, pages 2773-80.
<i>R</i>	CJ	Forbes, Ian T., "N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: A Novel, High-Affinity 5-HT _{2B} Receptor Antagonist," March 17, 1995, pages 855-57.
<i>R</i>	CK	Boulton, A. J., et al., "Heterocyclic Rearrangements. Part X. ¹ A Generalised Monocyclic Rearrangement," 1967, 2005-07.
<i>R</i>	CL	N. S. Magnuson, et al., "The Raf-1 serine/threonine protein kinase," Cancer Biology, vol. 5, 1994, pages 247-253.
<i>R</i>	CM	G. Daum, et al., "The ins and outs of Raf Kinases," TIBS 19, November 1994, pages 474-80.
<i>R</i>	CN	W. Kolch, et al., "Raf-1 protein kinase is required for growth of induced NIH/3T3 cells," Letters to Nature, vol. 349, January 31, 1991, page 226-28.
<i>R</i>	CO	M. Fridman, et al., "The Minimal Fragments of c-Raf-1 and NF1 That Can Suppress v-Ha-Ras-Induced Malignant Phenotype," The Journal of Biological Chemistry, vol. 269, no. 48, December 2, 1994, pages 30105-108.
<i>R</i>	CP	G. L. Bolton, et al., Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy, Annual Reports In Medicinal Chemistry, vol. 29, 1994, pages 165-74.

TJ Cuern 3/4/02



09/458,014

<i>R</i>	CQ	J. L. Bos, "ras Oncogenes in Human Cancer: A Review," Cancer Research, vol. 49, September 1, 1989, pages 4622-89.
<i>R</i>	CR	B. P. Monia, et al., "Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase," Nature Medicine, vol. 2, No. 6, June 1996, pages 668-75.
<i>R</i>	CS	Lee, et al., Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhiibitors," N.Y. Academy of Science, 1993, pages 149-70.
<i>R</i>	ST	F. Lepage, et al., "New N-aryl isoxazolecarboxamides and N-isoxazolybenzamides as anticonvulsant agents," Eur. J. Med. Chem, vol. 27, 1992, pages 581-93.
<i>R</i>	SU	Ridley, et al., "Actions of IL-1 are Selectively Controlled by p38 Mitogen-Activated Protein Kinase," The American Association of Immunologists, 1997, page 3165-73.
<i>R</i>	SV	Michaelis, Justus, Liebig Ann. Chem. (JLACBF) 397, 1913, 143.
Examiner <i>Xf Evans</i>		Date Considered <i>3/4/02</i>